LDEye Outpatient is an integrated solution for Non Alcoholic Fatty Liver Disease (NAFLD) patients consisting of:
1. A smart mobile application for coaching and monitoring patients' diet and exercise during their daily activities at home
2. A cloud-based web platform for the management of patients by doctors and dietitians with the capability of direct communication and the storage/analysis of data
High-performing non-fullerene acceptors and new molecules for ternary photovoltaic systems.
Zero voltage switching with constant output current for any load value without tuning or component replacement in wireless power transfer
A novel platform for production of Viral-like Particles (VLPs) used as a single vaccine against a range of viruses, including HIV, HPV, or Ebola. The invention combines two technical innovations; core platform to generate non-infectious VLPs based on the modification of Mumps or Parainfluenza 5 viruses, and a ‘pseudotyping’ technology to incorporate viral glycoproteins of choice on the surface of VLPs. As a proof of concept, the platform was used in development of modified VLPs against HIV. When used as a vaccine, VLPs boosted the production of anti-HIV antibodies better than the native virus.
Portable laser for skin surgery & aesthetic treatments achieved using off-the-shelf LEDs as light source.
SPARTA™ is a comprehensive nanoparticle analysis platform based on Raman spectroscopy providing simultaneous size, composition, and functionalisation analysis, as well as allowing live monitoring of dynamic reactions occurring on the surface of individual particles.
A novel multi-zonal anisotropic osteochondral scaffold has been developed which mimics the natural structure of articular cartilage with zone specific mechanical and biological properties
The present invention relates to a novel DNA delivery vector for targeted gene therapy, medical imaging and vaccination with increased efficacy over existing technologies. The platform comprises a phagemid hybrid with phage and recombinant adeno-associated virus (AAV) components.
A novel viral delivery vector with scope for more cost-effective commercial production over existing technologies. The platform comprises a phagemid hybrid with recombinant adeno-associated virus (AAV) components.
Researchers at Imperial College London have developed two novel modifications of bacteriophages to significantly improve their efficacy as vectors for targeted gene therapy, and exploit their advantages over eukaryotic viral vectors.